Demographic and clinical features by presence and duration of morning stiffness.
| Variables | Patients Meeting 2004 CID Criteria | p | ||
|---|---|---|---|---|
| Patients Meeting 2011 CID Criteria | ||||
| No MS, n = 554 | MS < 15 min, n = 53 | MS ≥ 15 min, n = 45 | ||
| Females | 431 (77.8) | 43 (71.1) | 36 (80.0) | 0.82 |
| ILAR category | 0.96 | |||
| Systemic arthritis | 20 (3.6) | 2 (3.8) | 2 (4.4) | |
| Persistent oligoarthritis | 219 (39.5) | 16 (30.2) | 15 (33.3) | |
| RF-negative polyarthritis | 153 (27.6) | 19 (35.8) | 13 (28.9) | |
| Extended oligoarthritis | 109 (19.7) | 10 (18.9) | 11 (24.4) | |
| RF-positive polyarthritis | 10 (1.8) | 0 (0.0) | 1 (2.2) | |
| Psoriatic arthritis | 14 (2.5) | 1 (1.9) | 1 (2.2) | |
| Enthesitis-related arthritis | 15 (2.7) | 3 (5.7) | 1 (2.2) | |
| Undifferentiated arthritis | 14 (2.5) | 2 (3.8) | 1 (2.2) | |
| Median (IQR) disease duration, yrs | 4.6 (2.3–8.8) | 3.9 (1.9–7.3) | 6.7 (3.1–9.1) | 0.17 |
| Median (IQR) age at visit, yrs | 9.7 (5.5–13.8) | 8.3 (4.8–11.8) | 10.6 (6.9–15.2) | 0.23 |
| Median (IQR) age at disease onset, yrs | 2.8 (1.7–5.8) | 3.2 (1.9–5.5) | 2.9 (1.9–7.0) | 0.55 |
| Patients with no. tender joints > 0 | 35 (6.3) | 3 (5.7) | 5 (11.1) | 0.442 |
| Patients with no. restricted joints > 0 | 111 (20.0) | 8 (15.1) | 6 (13.3) | 0.401 |
Data are n (%) unless otherwise indicated. CID: clinically inactive disease; MS: morning stiffness; ILAR: International League of Associations of Rheumatology; RF: rheumatoid factor; IQR: interquartile range.